Interventions for the management of obesity in people with bipolar disorder.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
20 07 2020
Historique:
entrez: 21 7 2020
pubmed: 21 7 2020
medline: 26 9 2020
Statut: epublish

Résumé

Bipolar disorder is one of the most common serious mental illnesses, affecting approximately 60 million people worldwide. Characterised by extreme alterations in mood, cognition, and behaviour, bipolar disorder can have a significant negative impact on the functioning and quality of life of the affected individual. Compared with the general population, the prevalence of comorbid obesity is significantly higher in bipolar disorder. Approximately 68% of treatment seeking bipolar patients are overweight or obese. Clinicians are aware that obesity has the potential to contribute to other physical health conditions in people with bipolar disorder, including diabetes, hypertension, metabolic syndrome, cardiovascular disease, and coronary heart disease. Cardiovascular disease is the leading cause of premature death in bipolar disorder, happening a decade or more earlier than in the general population. Contributing factors include illness-related factors (mood-related factors, i.e. mania or depression), treatment-related factors (weight implications and other side effects of medications), and lifestyle factors (physical inactivity, poor diet, smoking, substance abuse). Approaches to the management of obesity in individuals with bipolar disorder are diverse and include non-pharmacological interventions (i.e. dietary, exercise, behavioural, or multi-component), pharmacological interventions (i.e. weight loss drugs or medication switching), and bariatric surgery. To assess the effectiveness of interventions for the management of obesity in people with bipolar disorder. We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) and the Cochrane Central Register for Controlled Trials (CENTRAL) to February 2019. We ran additional searches via Ovid databases including MEDLINE, Embase, and PsycInfo to May 2020. We searched the World Health Organization (WHO) trials portal (International Clinical Trials Registry Platform (ICTRP)) and ClinicalTrials.gov. We also checked the reference lists of all papers brought to full-text stage and all relevant systematic reviews. Randomised controlled trials (RCTs), randomised at the level of the individual or cluster, and cross-over designs of interventions for management of obesity, in which at least 80% of study participants had a clinical diagnosis of bipolar disorder and comorbid obesity (body mass index (BMI) ≥ 30 kg/m²), were eligible for inclusion. No exclusions were based on type of bipolar disorder, stage of illness, age, or gender. We included non-pharmacological interventions comprising dietary, exercise, behavioural, and multi-component interventions; pharmacological interventions consisting of weight loss medications and medication switching interventions; and surgical interventions such as gastric bypass, gastric bands, biliopancreatic diversion, and vertical banded gastroplasty. Comparators included the following approaches: dietary intervention versus inactive comparator; exercise intervention versus inactive comparator; behavioural intervention versus inactive comparator; multi-component lifestyle intervention versus inactive comparator; medication switching intervention versus inactive comparator; weight loss medication intervention versus inactive comparator; and surgical intervention versus inactive comparator. Primary outcomes of interest were changes in body mass, patient-reported adverse events, and quality of life. Four review authors were involved in the process of selecting studies. Two review authors independently screened the titles and abstracts of studies identified in the search. Studies brought to the full-text stage were then screened by another two review authors working independently. However, none of the full-text studies met the inclusion criteria. Had we included studies, we would have assessed their methodological quality by using the criteria recommended in the Cochrane Handbook for Systematic Reviews of Interventions. We intended to combine dichotomous data using risk ratios (RRs), and continuous data using mean differences (MDs). For each outcome, we intended to calculate overall effect size with 95% confidence intervals (CIs). None of the studies that were screened met the inclusion criteria. None of the studies that were assessed met the inclusion criteria of this review. Therefore we were unable to determine the effectiveness of interventions for the management of obesity in individuals with bipolar disorder. Given the extent and impact of the problem and the absence of evidence, this review highlights the need for research in this area. We suggest the need for RCTs that will focus only on populations with bipolar disorder and comorbid obesity. We identified several ongoing studies that may be included in the update of this review.

Sections du résumé

BACKGROUND
Bipolar disorder is one of the most common serious mental illnesses, affecting approximately 60 million people worldwide. Characterised by extreme alterations in mood, cognition, and behaviour, bipolar disorder can have a significant negative impact on the functioning and quality of life of the affected individual. Compared with the general population, the prevalence of comorbid obesity is significantly higher in bipolar disorder. Approximately 68% of treatment seeking bipolar patients are overweight or obese. Clinicians are aware that obesity has the potential to contribute to other physical health conditions in people with bipolar disorder, including diabetes, hypertension, metabolic syndrome, cardiovascular disease, and coronary heart disease. Cardiovascular disease is the leading cause of premature death in bipolar disorder, happening a decade or more earlier than in the general population. Contributing factors include illness-related factors (mood-related factors, i.e. mania or depression), treatment-related factors (weight implications and other side effects of medications), and lifestyle factors (physical inactivity, poor diet, smoking, substance abuse). Approaches to the management of obesity in individuals with bipolar disorder are diverse and include non-pharmacological interventions (i.e. dietary, exercise, behavioural, or multi-component), pharmacological interventions (i.e. weight loss drugs or medication switching), and bariatric surgery.
OBJECTIVES
To assess the effectiveness of interventions for the management of obesity in people with bipolar disorder.
SEARCH METHODS
We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) and the Cochrane Central Register for Controlled Trials (CENTRAL) to February 2019. We ran additional searches via Ovid databases including MEDLINE, Embase, and PsycInfo to May 2020. We searched the World Health Organization (WHO) trials portal (International Clinical Trials Registry Platform (ICTRP)) and ClinicalTrials.gov. We also checked the reference lists of all papers brought to full-text stage and all relevant systematic reviews.
SELECTION CRITERIA
Randomised controlled trials (RCTs), randomised at the level of the individual or cluster, and cross-over designs of interventions for management of obesity, in which at least 80% of study participants had a clinical diagnosis of bipolar disorder and comorbid obesity (body mass index (BMI) ≥ 30 kg/m²), were eligible for inclusion. No exclusions were based on type of bipolar disorder, stage of illness, age, or gender. We included non-pharmacological interventions comprising dietary, exercise, behavioural, and multi-component interventions; pharmacological interventions consisting of weight loss medications and medication switching interventions; and surgical interventions such as gastric bypass, gastric bands, biliopancreatic diversion, and vertical banded gastroplasty. Comparators included the following approaches: dietary intervention versus inactive comparator; exercise intervention versus inactive comparator; behavioural intervention versus inactive comparator; multi-component lifestyle intervention versus inactive comparator; medication switching intervention versus inactive comparator; weight loss medication intervention versus inactive comparator; and surgical intervention versus inactive comparator. Primary outcomes of interest were changes in body mass, patient-reported adverse events, and quality of life.
DATA COLLECTION AND ANALYSIS
Four review authors were involved in the process of selecting studies. Two review authors independently screened the titles and abstracts of studies identified in the search. Studies brought to the full-text stage were then screened by another two review authors working independently. However, none of the full-text studies met the inclusion criteria. Had we included studies, we would have assessed their methodological quality by using the criteria recommended in the Cochrane Handbook for Systematic Reviews of Interventions. We intended to combine dichotomous data using risk ratios (RRs), and continuous data using mean differences (MDs). For each outcome, we intended to calculate overall effect size with 95% confidence intervals (CIs).
MAIN RESULTS
None of the studies that were screened met the inclusion criteria.
AUTHORS' CONCLUSIONS
None of the studies that were assessed met the inclusion criteria of this review. Therefore we were unable to determine the effectiveness of interventions for the management of obesity in individuals with bipolar disorder. Given the extent and impact of the problem and the absence of evidence, this review highlights the need for research in this area. We suggest the need for RCTs that will focus only on populations with bipolar disorder and comorbid obesity. We identified several ongoing studies that may be included in the update of this review.

Identifiants

pubmed: 32687629
doi: 10.1002/14651858.CD013006.pub2
pmc: PMC7386454
doi:

Banques de données

ClinicalTrials.gov
['NCT00344500']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013006

Informations de copyright

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Obesity (Silver Spring). 2014 Jul;22 Suppl 2:S5-39
pubmed: 24961825
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Am J Psychiatry. 2005 Sep;162(9):1744-6
pubmed: 16135638
Diabetes Care. 2011 Jul;34(7):1481-6
pubmed: 21593294
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Schizophr Res. 2007 Jul;93(1-3):99-108
pubmed: 17490862
Br J Psychiatry. 1995 May;166(5):654-9
pubmed: 7620753
Br J Psychiatry. 2017 Sep;211(3):175-181
pubmed: 28684403
Adv Ther. 2007 Jan-Feb;24(1):123-34
pubmed: 17526469
N Engl J Med. 2005 Sep 22;353(12):1209-23
pubmed: 16172203
Pharmacotherapy. 2000 Mar;20(3):270-9
pubmed: 10730683
CMAJ. 2007 Apr 10;176(8):S1-13
pubmed: 17420481
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
Hypertension. 2005 Jun;45(6):1035-41
pubmed: 15897373
Aust N Z J Psychiatry. 2005 Jun;39(6):479-86
pubmed: 15943650
Am J Health Syst Pharm. 2011 Nov 1;68(21):2029-37
pubmed: 22011982
Cochrane Database Syst Rev. 2014 Aug 08;(8):CD003641
pubmed: 25105982
World J Gastroenterol. 2014 Aug 14;20(30):10577-84
pubmed: 25132778
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Lancet. 2007 Jan 6;369(9555):71-7
pubmed: 17208644
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Acta Psychiatr Scand. 1999 Jul;100(1):3-16
pubmed: 10442434
Psychopharmacol Bull. 2011;44(1):5-17
pubmed: 22506436
Bipolar Disord. 2010 Nov;12(7):727-40
pubmed: 21040290
J Affect Disord. 2010 Nov;126(3):366-87
pubmed: 20541810
Metabolism. 2015 Nov;64(11):1376-85
pubmed: 26342499
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Bipolar Disord. 2006 Oct;8(5 Pt 1):503-7
pubmed: 17042889
JAMA. 2015 Mar 24-31;313(12):1213-4
pubmed: 25803343
Trials. 2015 Feb 12;16:47
pubmed: 25887033
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003818
pubmed: 15846683
Eur Neuropsychopharmacol. 2005 Jan;15(1):13-21
pubmed: 15572269
J Clin Psychiatry. 2006 Aug;67(8):1253-60
pubmed: 16965204
J Clin Psychiatry. 2007;68 Suppl 4:34-9
pubmed: 17539698
Neuropsychiatr Dis Treat. 2007;3(5):579-87
pubmed: 19300587
J Child Adolesc Psychopharmacol. 2017 Jun;27(5):440-444
pubmed: 28339282
BMC Psychiatry. 2016 Oct 3;16(1):341
pubmed: 27716110
Acta Psychiatr Scand. 2009 Mar;119(3):171-9
pubmed: 19178394
Obes Rev. 2001 Aug;2(3):173-82
pubmed: 12120102
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
J Clin Psychopharmacol. 2016 Apr;36(2):163-8
pubmed: 26872112
J Clin Psychiatry. 2016 Feb;77(2):e183-9
pubmed: 26930534
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006629
pubmed: 21154372
Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79
pubmed: 21924589
J Clin Psychiatry. 2007;68 Suppl 4:8-13
pubmed: 17539694
J Clin Psychiatry. 2009;70 Suppl 3:12-21
pubmed: 19570497
Prim Care Companion J Clin Psychiatry. 2010;12(5):
pubmed: 21274359
Psychiatr Serv. 2013 Aug 1;64(8):737-44
pubmed: 23584716
Ther Clin Risk Manag. 2008 Aug;4(4):713-20
pubmed: 19209252
Bipolar Disord. 2007 Jun;9(4):426-34
pubmed: 17547588
Ann Clin Psychiatry. 2011 Aug;23(3):193-201
pubmed: 21808751
Bipolar Disord. 2015 Jun;17(4):424-37
pubmed: 25495748
J Clin Psychiatry. 2015 Feb;76(2):163-9
pubmed: 25742203
Community Ment Health J. 2011 Dec;47(6):688-93
pubmed: 21240554
Psychiatry Res. 1997 Dec 5;73(3):159-71
pubmed: 9481807
Mens Sana Monogr. 2010 Jan;8(1):53-68
pubmed: 21327170
Am J Psychiatry. 2015 Apr;172(4):344-52
pubmed: 25827032
Am J Health Syst Pharm. 2015 May 1;72(9):697-706
pubmed: 25873617
J Psychopharmacol. 2016 Aug;30(8):717-48
pubmed: 27147592
Arch Gen Psychiatry. 2006 Jul;63(7):824-30
pubmed: 16818872
Psychiatr Serv. 2010 Aug;61(8):774-82
pubmed: 20675835
J Clin Psychiatry. 2004 May;65(5):634-51, quiz 730
pubmed: 15163249
Can J Psychiatry. 2001 Apr;46(3):273-81
pubmed: 11320682
Am J Psychiatry. 2003 Jan;160(1):112-7
pubmed: 12505809
Pharmacoeconomics. 2003;21(9):601-22
pubmed: 12807364
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Agnes Tully (A)

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.

Siobhan Smyth (S)

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.

Yvonne Conway (Y)

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.

John Geddes (J)

Department of Psychiatry, University of Oxford, Oxford, UK.

Declan Devane (D)

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.

John P Kelly (JP)

Pharmacology and Therapeutics, National University of Ireland Galway, Galway, Ireland.

Fionnuala Jordan (F)

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH